Build status - In Progress

Open label comparison of injectable buprenorphine (CAM2038 Brixadi ) and naltrexone (Vivitrol ) for opioid use disorder

Recruiting
99 years or below
All
Phase 2
200 participants needed
1 Location

Brief description of study

Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or reports of two or more periods of 3 days of opioid use in the 3rd (last) month of treatment, is late for more than 2 weeks for XRNTX or XRBUP treatment, or drops out of treatment prior to the 3rd injection, will be classified as treatment failures; otherwise, they will be classified as a treatment success. Test an integrated brain-behavior model of relapse vulnerability in OUD; ASI composite scores; effects of Group and neural change variables on other substance use outcomes

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: opioid use disorder
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 843403

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center